ARTV vs CRBU
ARTV: Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials. CRBU: Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood cancer patients.
Side-by-side fundamentals
| Metric | ARTV | CRBU | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.02 | $1.66 | |
| Market cap as of 2026-07-23 | $487M | $165M | |
| PEG as of 2026-07-23 | -0.15 | n/a | |
| Net margin as of 2026-07-23 | -26045.0% | -1189.1% | CRBU higher |
| Operating margin as of 2026-07-23 | -26805.6% | -1257.4% | CRBU higher |
| ROE as of 2026-07-23 | -60.2% | -100.1% | ARTV higher |
| ROA as of 2026-07-23 | -52.4% | -72.0% | ARTV higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | CRBU lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +13.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -7.0% | |
| Beta as of 2026-07-23 | 6.02 | 2.33 | |
| 1-year return as of 2026-07-22 close | +292.2% | -20.3% | ARTV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.